Combination treatment for advanced non-squamous lung cancer
This trial tests two investigational drugs combined as a first treatment for people with a type of lung cancer called non-squamous non-small-cell lung cancer that has spread. The aim is to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with non-squamous non-small-cell lung cancer that has spread to other parts of the body.
- You have not had any prior treatment for advanced or metastatic lung cancer, but you may have had prior surgery or radiation.
- You have not had immunotherapy before, meaning drugs that boost your immune system to fight cancer.
- You have not had certain gene mutations (like EGFR or ALK) for which approved targeted treatments exist.
- You do not have active brain metastases, but treated and stable brain lesions may be allowed.
- You are generally healthy enough to perform daily activities (ECOG score of 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new drug combination (RC148 plus chemotherapy) with a standard immunotherapy (tislelizumab) plus chemotherapy for people with a common type of lung cancer. It tests whether the new combination works better as a first treatment for advanced cancer.
This trial tests a new drug combination for people with advanced non-squamous non-small cell lung cancer who have not had treatment before. It compares the new drug with a standard immunotherapy, both given with chemotherapy, to see which is more effective.
This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.
This study tests a new drug called telisotuzumab adizutecan against the usual treatments for people with a type of lung cancer that has spread and has not responded to previous therapy. It may be an option if your cancer has a specific marker and you have not had certain other conditions.
This trial tests a new drug (RC148) plus chemotherapy against another drug (Tislelizumab) plus chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or can't be removed. It's for those who haven't had treatment for advanced disease yet.
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Hear when a new Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.